Study Links Elevated Lipoprotein(a) Levels to Increased Cardiovascular Risk
New research involving more than 20,000 patients from three major NIH studies has revealed that elevated levels of Lipoprotein(a) [Lp(a)] may contribute to cardiovascular risk that persists despite standard treatments. The findings were presented at the Society for Cardiovascular Angiography & Interventions (SCAI) 2026 Scientific Sessions and the Canadian Association of Interventional Cardiology Summit in Montreal. Lp(a) is a cholesterol-carrying particle in the blood, similar to LDL, often referred to as "bad" cholesterol, but it includes an additional protein that may increase the risk of cardiovascular disease. High levels of Lp(a) are primarily determined by genetics and can elevate cardiovascular risk even when conventional cholesterol measurements are normal. Approximately one in five individuals has high Lp(a), yet most are unaware of their condition as it typically does not present symptoms. Researchers have long acknowledged the link between elevated Lp(a) and cardiovascular disease, but further investigation is needed to understand how well Lp(a) predicts future risk in individuals with and without existing heart disease. For this analysis, researchers examined plasma samples from 20,070 participants aged 40 and older who had participated in the ACCORD, PEACE, and SPRINT NIH randomized trials. The samples were analyzed in a specialized laboratory using a standardized assay, with results reported in nmo/L. Participants were categorized based on their Lp(a) levels and whether they had pre-existing heart disease. The study focused on major adverse cardiovascular events (MACE), which included myocardial infarction, stroke, coronary revascularization, or cardiac death. Over a median follow-up of 3.98 years, 1,461 MACE events occurred. An Lp(a) level of 175 nmo/L or higher was found to be independently associated with an increased risk of MACE, cardiovascular death, and stroke, although it was not linked to a higher risk of heart attack. The association was stronger among participants with existing heart disease compared to those without. Dr. Subhash Banerjee, an interventional cardiologist, emphasized that this research quantifies the specific Lp(a) level that significantly raises the risk of major cardiovascular events. He noted that patients can undergo a simple, low-cost blood test to check for this genetic condition. If elevated levels are detected, it is crucial for patients to collaborate with their healthcare providers to manage LDL cholesterol and other cardiovascular risk factors effectively. The researchers also highlighted the value of stored biospecimens in uncovering new insights from completed clinical trials and plan to explore additional patient groups in future studies, including those with chronic kidney disease and peripheral artery disease.




